2Q PREVIEW: Bristol-Myers Squibb still recovering from patent losses
This article was originally published in Scrip
Executive Summary
With the loss of US patent protection on two big drugs in 2012, Bristol-Myers Squibb is set to report lower sales and profit from a year earlier when the company announces second-quarter results this week.